Tarodyn en es it fr

Tarodyn Brand names, Tarodyn Analogs

Tarodyn Brand Names Mixture

  • No information avaliable

Tarodyn Chemical_Formula


Tarodyn RX_link


Tarodyn fda sheet

Tarodyn FDA

Tarodyn msds (material safety sheet)

Tarodyn MSDS

Tarodyn Synthesis Reference

No information avaliable

Tarodyn Molecular Weight

318.431 g/mol

Tarodyn Melting Point

192.5 oC

Tarodyn H2O Solubility

No information avaliable

Tarodyn State


Tarodyn LogP


Tarodyn Dosage Forms

Liquid; Tablet

Tarodyn Indication

For use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation.

Tarodyn Pharmacology

Glycopyrrolate decreases acid secretion in the stomach. Hence it can be used for treating ulcers in the stomach and small intestine, in combination with other medications. In anesthesia, glycopyrrolate injection serves as a preoperative antimuscarinic operation that reduces salivary, tracheobronchial, and pharyngeal secretions, as well as decreases the acidity of gastric secretions blocks cardiac vagal inhibitory reflexes during intubation

Tarodyn Absorption

Rapidly absorbed (1-2 minutes) after intravenous injection

Tarodyn side effects and Toxicity

Side effects include dry mouth, difficult urinating, heachaches, diarrhea and constipation. The medication also induces drowsiness or blurred vision. LD50=709 mg/kg (rat, oral).

Tarodyn Patient Information

No information avaliable

Tarodyn Organisms Affected

Humans and other mammals